Drugs / rBV A/B
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01940315 Comparator | Oct 2017 → Mar 2019 | botulism | DynPort Vaccine Company LLC, A GDIT Company | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rBV A/B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01940315 ↗ |
| Modality | Vaccine | “Recombinant Botulinum Vaccine A/B” NCT01940315 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM)” NCT01940315 ↗ |